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Interleukin-33 regulates intestinal 
inflammation by modulating 
macrophages in inflammatory 
bowel disease
Dong Hyuk Seo1,2,3, Xiumei Che1,2,3, Min Seob Kwak4,5, Soochan Kim1,3, Jae Hyeon Kim1,2, 
Hyun Woo Ma1,2, Da Hye Kim1,3, Tae Il Kim1, Won Ho Kim1, Seung Won Kim1,2,3 & Jae Hee 
Cheon1,2,3
Interleukin 33 (IL-33) that signals through the ST2 receptor has emerged as a critical modulator in 
several inflammatory disorders, including inflammatory bowel disease (IBD). However, the precise 
mechanisms by which IL-33 modulates IBD are controversial. The aim of this study was thus to clarify 
the role of IL-33 in IBD. The plasma levels of IL-33 were significantly decreased, but soluble ST2 
levels were increased in patients with IBD compared to healthy individuals. Moreover, IL-33 restored 
goblet cell numbers and induced macrophage switching from the M1 to the M2 phenotype. These 
effects were sufficient to ameliorate colitis in dextran sodium sulfate, trinitrobenzene sulfonic acid, 
and peritoneal cavity cell transfer models. IL-33 facilitated goblet cell restoration via modulating 
macrophages toward the M2 phenotype. In addition, wound healing was significantly faster in IL-33-
treated human monocyte-derived macrophages than in control cells, which could be attributed to 
increased polarisation into M2 macrophages. We found that patients with IBD show decreased serum 
levels of IL-33 compared with healthy individuals and that IL-33 can attenuate colitis and aid tissue 
repair in mice. The mechanism by which IL-33 exerts these effects appears to involve the stimulation of 
differentiation of goblet cells and M2 macrophages.
Inflammatory bowel diseases (IBDs) are chronic relapsing disorders of the intestine that are caused by com-
plex interactions of environmental and genetic factors, along with subsequent changes in immune dysregulation. 
Recently, interleukin 33 (IL-33), a novel member of the IL-1 family and an alarmin cytokine that acts in response 
to various kinds of tissue damage1, has emerged as a critical modulator in several autoimmune and inflammatory 
disorders, including IBD. However, the role of IL-33 in IBD has not yet been clearly defined. Controversial data 
have been obtained regarding whether serum IL-33 levels correlate with IBD activity2–4. It is also a matter of 
controversy whether the IL-33 concentration is elevated in the inflamed intestinal lesions of patients with IBD4–6. 
Although there are several studies that have been performed in animal models to investigate the proinflammatory 
functions of IL-33 in colitis7–9, these studies have yielded conflicting results9–14. The role of IL-33 in the intestine 
seems to depend on the stage of inflammation, and can be either detrimental or protective9, 13, 15. Nevertheless, 
emerging evidence indicates that IL-33 plays a role in epithelial restoration, repair, and mucosal healing in ulcer-
ative colitis (UC) and Crohn’s disease (CD)11.
Once the epithelial layer is damaged, it responds by restoring the continuity of the layer and the integrated 
structure via a complex regeneration process16. Goblet cells and macrophages play key roles in this tissue remod-
elling17, 18. Goblet cells, otherwise known as mucin secretory intestinal epithelial cells (IECs)19, form mucous 
layers and perform a critical barrier function. Classically activated macrophages (M1 macrophages) can be 
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differentiated into alternatively activated macrophages (M2 macrophages), the latter of which are considered to 
produce only low levels of proinflammatory cytokines and to function more in the resolution of inflammation 
and tissue repair20. IL-33 has been reported to induce goblet cell hyperplasia both in vitro and in vivo through T 
helper 2 (Th2) cell expansions and through regulatory T cell (Treg) induction8, 21. IL-33 has also been shown to 
skew macrophages from the M1 to the M2 phenotype during airway inflammation22. However, these effects of 
IL-33 on goblet cells and macrophages have not yet been conclusively demonstrated in IBD.
Recently, it was reported that IL-33 colocalised with F4/80+ myeloid-derived cells in the inflamed intestinal 
lamina propria of mice in an oxazolone colitis model10. Given this finding, we speculated that IL-33 can directly 
modulate intestinal immune responses by driving the M1-to-M2 macrophage switch and macrophage-goblet cell 
cross-talk. Therefore, the aim of our study was to investigate the associations between IL-33 and IBD by exploring 
whether IL-33 contributes to the resolution of colitis and tissue repair by functional phenotype modulation of 
goblet cells and macrophages. To this end, we assessed the effect of IL-33 on colitis using well-established acute 
murine models of colitis. We also analysed clinical samples from patients with IBD.
Results
IL-33 expression is downregulated, but soluble ST2 expression is upregulated in serum of 
patients with IBD. ST2, an IL-33 receptor, is mainly present as two forms: ST2L, which is membrane-bound, 
and sST2, which is soluble. sST2 has been shown to compete for IL-33 binding and to inhibit receptor signalling 
as a decoy receptor for IL-334. Thus, we firstly examined circulating IL-33 and sST2 levels in serum samples 
from normal control subjects and patients with various IBDs, including CD, UC, and Behçet’s disease (BD), to 
determine whether IL-33 levels were correlated with IBD. For protein quantitation, we used an enzyme-linked 
immunosorbent assay (ELISA). The demographic and clinical characteristics of the patients with IBD are shown 
in Table S1. As shown in Fig. 1a−d, we found that the serum IL-33 levels (mean) in patients with IBD were 
lower than those in normal controls (P < 0.012: normal controls, 0.513 ± 0.665 ng/ml; IBD, 0.242 ± 0.436 ng/ml; 
CD, 0.381 ± 0.582 ng/ml; UC, 0.185 ± 0.394 ng/ml; intestinal BD, 0.160 ± 0.229 ng/ml), whereas the sST2 levels 
in patients with IBD were higher than those in normal controls (P < 0.001: normal controls, 4.246 ± 0.737 ng/
ml; IBD, 5.344 ± 1.162 ng/ml; CD, 5.110 ± 1.054 ng/ml; UC, 5.581 ± 1.169 ng/ml; BD, 5.214 ± 1.174 ng/ml). These 
findings were consistent with those of several previous studies2, 4. In particular, patients with UC and intestinal 
BD showed significantly different serum IL-33 levels compared to healthy controls (P < 0.010 and P < 0.005, 
respectively). Moreover, the serum IL33/sST2 ratio was markedly reduced in patients with UC and patients 
with intestinal BD (Fig. S1a). Interestingly, these findings are the opposite of what was observed with serum 
IL-33 levels in patients with IBD. To evaluate whether IL-33 expression is up- or downregulated in the inflamed 
colon, we examined IL-33 gene expression levels in human and murine tissue samples from inflamed colons. 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis revealed that IL-33 expression 
was upregulated in colonic mucosal samples from patients with IBD (Fig. S2a) and in colon tissue samples from 
dextran sodium sulfate (DSS)-treated mice (Fig. S2b) compared with the respective controls. We hypothesise 
that increased IL-33 levels during colitis might result from a compensatory mechanism against tissue damage by 
active inflammation itself. This increase might also result from secondary changes in response to other cytokines 
produced during inflammation23.
Figure 1. Levels of circulating IL-33 and soluble ST2 (sST2). Serum IL-33 and sST2 concentrations were 
determined in duplicate by enzyme-linked immunosorbent assay (ELISA). Two different anti-IL-33 antibodies 
were used, each of which recognized a different IL-33 epitope. The levels of IL-33 (a,c) and sST2 (b,d) were 
assessed by ELISA in serum samples from normal controls (NC) and patients with Crohn’s disease (CD), 
ulcerative colitis (UC), and Behçet’s disease (BD). The error bars represent the SEMs. (e,f) Correlations between 
serum IL-33 (e) and sST2 (f) levels and clinical disease activity of inflammatory bowel disease (IBD). **P < 0.01 
vs. NC, ***P < 0.005 vs. NC as assessed by ANOVA. NC, normal control; CDAI, Crohn’s disease activity index; 
DAIBD, disease activity index for intestinal Behçet’s disease.
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We next analysed disease severity by calculating various disease-appropriate activity scores. Linear correlation 
analysis revealed that the serum sST2 levels (r = 0.283, P = 0.026) were significantly associated with the pMayo 
score in patients with UC (Fig. 1e), whereas serum IL-33 levels were not (Fig. 1f). However, no significant corre-
lations were observed between the serum IL-33/sST2 ratio and the partial Mayo scoring index (pMayo) score in 
patients with UC, the Crohn’s disease activity index (CDAI)24, in patients with CD, or the disease activity index in 
patients with intestinal Behçet’s disease (DAIBD)25 (Fig. S1b).
IL-33 attenuates colitis via directly modulating goblet cell and macrophage functions. Since 
IL-33 has been localised to enterocytes and the lamina propria of IBD patients and healthy controls2, 4, we hypoth-
esised that IL-33 might directly modulate the differentiation of enterocytes and macrophages into goblet cells and 
M2 macrophages, respectively, but not through modulation of Treg and Th2. The pathogenesis of DSS-induced 
colitis, a model of UC-like disease, is considered to be driven by macrophages26. Therefore, to assess the effects of 
IL-33 on enterocyte and macrophage differentiation, mice were i.p. injected daily with mrIL-33 for 5 days after 
DSS treatment. In our study, mice in the IL-33-treated groups displayed significantly improved body weight 
recovery, longer colons, lower disease activity index (DAI) and histological score than mice in the vehicle-treated 
control groups (Figs 2a–c and S3). To explore the effects of IL-33 administration on goblet cells, we performed 
periodic acid-Schiff (PAS) staining. The colon sections from DSS-administered mice exhibited fewer goblet cells 
than colon sections from sham controls; moreover, more hypotrophic goblet cells containing less mucus were 
evident in the DSS colon sections. In contrast, the goblet cells showed near complete restoration in colon sections 
from the mrIL-33-treated DSS groups (Fig. 2d). Consistently, the mrIL-33-treated groups also showed increased 
mRNA expression of mucin 2 (Muc2) in the colon; this gene encodes a major macromolecular constituent of 
intestinal mucus and is a known determinant of goblet cell morphology (Fig. 2e). We next examined whether 
IL-33 acts systemically on M2 polarisation of macrophages and T cell differentiation. To this end, we analysed 
the M2 population (CD206+) in the macrophages (F4/80+) from peritoneal cavity cells (PCCs) and the Treg 
Figure 2. Effects of IL-33 on dextran sodium sulfate (DSS)-induced colitis in mice. (a) Body weight changes. 
The weight of each mouse was followed daily. (b) Effects of IL-33 on colon length. (c) Effects of IL-33 on the 
disease activity index (DAI). Disease activity at day 7 was scored according to the criteria outlined in the 
Materials and Methods. (d) Representative image of periodic acid-Schiff (PAS)-stained goblet cells in the colon. 
(e,h,i) mRNA expression in the mouse colon. mRNA expression of Muc2 (e), M2 markers (Cd206, Cd163, 
and Arg1) (h), and Tnfa (i) were evaluated by quantitative RT-PCR. (f) Flow cytometry analysis of the M2 
macrophage (CD206+) populations in peritoneal cavity cells (PCCs) from treated mice. (g) Flow cytometry 
analysis of the Treg (Foxp3+) and Th1 (Gata3+) populations in the spleens of treated mice. Data are presented as 
means ± SE (n = 5 mice/group). Recombinant IL-33 (mrIL-33) was i.p. injected daily (0.2 μg/mouse) for 5 days 
after treatment with 3% (w/v) DSS. #P < 0.05 vs. Sham control, *P < 0.05 vs. DSS as assessed by ANOVA.
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(Foxp3+) and Th2 (Gata3+) populations in T cells (CD3+) from the spleens of sacrificed mice, respectively. PCCs 
from mrIL-33 + DSS-treated mice had a higher percentage of CD206+ macrophages compared with PCCs from 
vehicle + DSS-treated mice (Fig. 2f). As shown in Fig. 2g, however, the percentages of splenic Treg cells and Th2 
cells were not significantly changed by mrIL-33 administration in the DSS-treated mice, contrary to the results 
of a previous study8, 21. These findings suggest that IL-33–mediated amelioration of colitis might not be associ-
ated with an enhanced Treg response in our mouse colitis models different from previous studies27–29, implying 
that other factors might contribute to the tissue protection observed after mrIL-33 treatment of colitis. We next 
hypothesised that IL-33 directly modulates goblet cells and macrophages to exert its protective effects against 
colitis. Consistent with this hypothesis, we observed upregulation of M2 markers such as Cd206, Cd163, and 
Arg1, but downregulation of M1 markers such as tumour necrosis factor alpha (Tnfa), in colon tissue samples from 
mrIL-33-treated mice (Fig. 2h,i).
Since the role of IL-33 in mouse colitis is controversial and IL-33 has been reported to inhibit Th1 and pro-
mote Th2 profiles29, we next evaluated the effect of IL-33 on another Th1-mediated CD-like colitis model using 
2,4,6-trinitrobenzene sulfonic acid (TNBS). The mrIL-33-treated mice exhibited slightly longer life spans than 
the TNBS-treated mice, although this trend was not statistically significant (Fig. S4), suggesting that IL-33 exerts 
protective effects against Th1-mediated colitis. Although TNBS-induced colitis is Th1-mediated, the major source 
of IL-33 in the colonic tissues of TNBS-treated mice is infiltrated macrophages11. Moreover, IL-33 can signal via 
the myeloid differentiation primary response gene 88 (MyD88)-dependent pathway, which is important for the 
induction of mucosal inflammation at the onset of colitis15. To assess the effects of IL-33 on enterocyte differenti-
ation early in colitis and the contribution of MyD88 to these effects, we i.p. injected wild-type or MyD88-deficient 
mice with mrIL-33 after low-dose TNBS administration. These mice were sacrificed before the development of 
severe colitis to investigate the effects of IL-33 at the onset of inflammation. In this setting, mrIL-33 adminis-
tration restored body weight and reduced disease activity in both wild and MyD88-deficient mice (Figs 3a and 
S5a), although the body weight loss was induced by mrIL-33 administration in both groups in the early stage 
(until day 3) of colitis in agreement with the other study9, 12, 13, 30. These results suggest that IL-33 acts very early, 
before the development of severe colitis; moreover, they suggest that IL-33 acts independently of the MyD88 
pathway. To explore changes in enterocytes after mrIL-33 administration in the setting of colitis development, 
we assessed goblet cells using PAS staining. Similar to what was observed in DSS-induced colitis, fewer goblet 
cells were observed in the colon sections from TNBS-administered WT and MyD88-deficient mice compared to 
sham controls; moreover, more of the goblet cells were hypotrophic. However, goblet cells in the mrIL-33-treated 
TNBS-treated group showed near complete recovery in both wild-type and MyD88-deficient mice (Fig. 3b). 
Consistent with these findings, colon tissue samples from TNBS-administered mice showed reduced mRNA 
expression of Muc2, whereas mrIL-33 administration markedly restored the mRNA expression of Muc2 in the 
colon tissue samples from both groups of mice (Fig. S5b). These results suggest that goblet cell modulation by 
IL-33 is independent of the MyD88 pathway during colitis. To further confirm our in vivo findings, we examined 
the mRNA expression level of MUC2 in colon IECs, HT-29 cells, and SW480 cells using qRT-PCR. Previous stud-
ies indicated that perturbed homeostasis between commensal bacteria and mucosal immunity, such as aberrant 
TLR modulation such as TLR4 by lipopolysaccharide (LPS), is an important stimulator of cytokines including 
TNF-α, may contribute to the development of gut inflammation and IBD31–33. LPS treatment reduces MUC2 
mRNA expression as previously described34. However, MUC2 mRNA expression was consistently upregulated 
in hrIL-33-treated cells compared with the appropriate controls (Fig. 3c). Additionally, Kruppel-like factor (KLF) 
4 mRNA, required for the terminal differentiation of goblet cells in the colon35, was upregulated in recombinant 
IL-33-treated cells (Fig. 3d) and in the colon of mice treated with TNBS compared with the controls (Fig. 3e). 
Taken together, our results indicate that goblet cell modulation by IL-33 might be directly influenced by IL-33 
itself or by other non-T cells, such as macrophages.
IL-33 directly switches macrophages from the M1 to the M2 phenotype; this switch is sufficient 
to ameliorate colitis and goblet cell differentiation. We next determined if IL-33 directly affects M2 
polarisation of macrophages, a process that accelerates wound repair and suppresses proinflammatory cytokines. 
M2 polarisation has been shown to be potently induced by IL-33 through type 2 cytokines and by regulatory T 
cells derived from T helper or innate lymphoid cells36, 37. Since macrophages express the ST238, we reasoned that 
IL-33 might directly promote M2 polarisation of macrophages. To test this hypothesis, we peritoneally adminis-
tered mrIL-33 to naïve mice and isolated PCCs 3 days later. Next, we isolated F4/80+ cells from the PCCs using 
fluorescence activated cell sorting (FACS) and transferred the F4/80+ cells to TNBS-treated mice. We found 
that mrIL-33 administration markedly increased the numbers of CD206+ cells isolated from PCCs (Figs 4a and 
S6a). However, the numbers of Foxp3+ cells were only slightly increased and the numbers of Gata3+ cells did not 
exhibit any significant changes compared with the numbers isolated from the spleens of naïve mice (Fig. 4b). 
Notably, IL-33-F4/80+-transferred TNBS-treated mice exhibited significantly better body weight retention, longer 
colons, and decreased disease severity and histological score (Figs 4c−e and S6b). As expected, IL-33-F4/80+ 
PCC-treated mice exhibited significant increases in the percentages of CD206+ cells in the F4/80+ populations 
isolated from the colons compared with PBS-F4/80+-treated mice (Figs 5a and S6c). However, unexpectedly, 
IL-33-F4/80+ PCC-treated mice showed modest, but decreases in the numbers of Gata3 (Th2) and Foxp3 (Treg) 
positive cells in the spleen compared to PBS-F4/80+ PCC-treated mice (Fig. 4f). These findings indicate that 
IL-33 might ameliorate colitis in association with increased M2 macrophages, but irrespective of a Th1-to-Th2 
shift or Treg activity. IL-33-F4/80+ PCC treatment inhibited the expression of typical M1 markers such as Tnfa 
in the colon tissue samples from TNBS-treated mice, while IL-33-F4/80+ PCC treatment induced mRNA expres-
sion of typical M2 markers including Cd206, Cd163, transforming growth factor beta (Tgfb), and Il10 (Figs 5b,c 
and S7a). In particular, IL-33-F4/80+ PCC treatment also upregulated Klf4 and Muc2 expression (Figs 5d and 
S7b), suggesting that IL-33 modulates the phenotypes of activated macrophages and recovers the functions of 
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resident enterocytes such as goblet cells. Consistently, histological examinations of the colonic tissue samples 
revealed significantly reduced colitis and hypotrophic goblet cells in IL-33-F4/80+ PCC-treated mice compared 
with control mice (Fig. 5e). To confirm whether macrophages directly facilitate goblet cell differentiation, we 
treated mature THP-1 monocyte-derived macrophages with hrIL-33 and LPS, harvested the conditioned media 
from the macrophage culture after 48 h, and treated HT-29 and SW480 with the conditioned media for 48 h. 
As shown in Fig. 6a and b, HT-29 and SW480 cells treated with the LPS + hrIL-33-treated conditioned media 
showed higher MUC2 expression (4.2 and 2.1 folds, respectively) and, concordantly, higher KLF4 expression 
when compared to groups treated with LPS-treated conditioned media (1.5 and 1.4 folds, respectively). Of note, 
a markedly increased expression of MUC2 and KLF4 was observed in the LPS + hrIL-33-treated conditioned 
media-treated cells than the cells directly treated with LPS + hrIL-33-treated when compared to control groups 
(1.9 and 2.7 folds in HT-29 cells; 1.8 and 1.5 folds in SW480 cells, respectively). These results indicate that goblet 
cell modulation by IL-33 might be directly influenced by macrophages, which was first confirmed in this study.
IL-33 impacts M2 macrophage polarisation from PBMCs of patients with IBD and drives wound 
healing. To investigate whether IL-33 directly impacts M2 macrophage polarisation in inflamed mucosal 
samples from patients with IBD, colon tissue sections were coimmunostained with anti-IL-33 and anti-CD206 
antibodies. Inflamed colonic tissue sections from patients with UC revealed that mononuclear cells with nuclear 
staining of IL-33 widely infiltrated into the lamina propria and were not restricted to close proximity to entero-
cytes. In contrast, healthy colon tissue sections exhibited exclusively close proximity of IL-33 staining (Fig. S8a), 
consistent with a previous study4. Subsequent immunostaining revealed that the IL-33-immunopositive cells 
coincided with a considerable number of CD206+ cells with abundant cytoplasm, characteristics that are typical 
Figure 3. MyD88 independent effects of IL-33 on goblet cell restoration in inflammation. (a,b,e) Effects 
of IL-33 on colitis and goblet cells in the colon of wild-type (WT) and MyD88 deficient (MyD88−/−) mice 
after low-dose 2,4,6-trinitrobenzenesulfonic acid (TNBS) administration (n = 5 mice/group). To assess the 
effects of IL-33 on enterocyte early in colitis, 100 µl TNBS solution (1.8% (w/v)) in 40% ethanol was injected 
into the colon of each mouse. (a) Changes in body weight. The weight of each mouse was followed daily. (b) 
Representative image of periodic acid-Schiff (PAS) staining of the colonic mucosa for goblet cells. Original 
magnification: x200. (c,d) Effects of IL-33 on MUC2 (c) and KLF4 (d) mRNA expression in human colonic 
epithelial cells. HT-29 cells were treated with vehicle (Veh) or lipopolysaccharide (LPS, 100 ng/ml), with or 
without human recombinant IL-33 (hrIL-33), for 4 hours. Total RNA was extracted and analysed by quantitative 
RT-PCR. Target mRNA expression levels were normalised to that of β-actin. Results are representative of 
two independent experiments. (e) Effects of IL-33 on Klf4 mRNA expression in the mouse colon. Values 
are expressed as means; error bars represent ±SD. #P < 0.05 vs. Sham control, *P < 0.05 vs. TNBS or LPS, 
**P < 0.01 vs. TNBS or LPS, ***P < 0.005 vs. LPS as assessed by ANOVA. Veh, injected with vehicle; IL-33, 
once injected with mrIL-33 (1 μg/mouse) or hrIL-33 (20 ng/ml); TNBS, injected with TNBS.
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of tissue macrophages (Figs 6c and S8b). To determine whether IL-33 directly drives macrophages toward the 
M2 phenotype in humans, we treated monocytes isolated from PBMCs of patients with IBD with granulocyte 
macrophage-colony stimulating factor (GM-CSF) for 72 h and then with hrIL-33. IL-33 clearly induced CD206+ 
expression in human monocyte-derived macrophages (MDMs), while an IL-33 antagonist completely blocked 
this induction of CD206+ expression (Fig. 6d). Next, we performed a wound healing assay to evaluate the effects 
of hrIL-33-treated MDMs on wound repair. hrIL-33-treated MDMs were cocultured with scraped (i.e. wounded) 
HT-29 cells. We found that hrIL-33-treated macrophages mediated significantly greater wound closure in the 
epithelial cells compared with vehicle-treated macrophages (Figs 6e and S9). In addition, the wound closure rates 
were higher in control macrophage-treated groups (Veh) than in untreated controls, which is consistent with 
findings of a previous study that activation of macrophages with LPS induced a concentration-dependent increase 
the wound healing rate in cultured gastric epithelial cells39. These results demonstrate that macrophages play a 
prominent role in wound healing and that macrophage phenotype plasticity can be modulated by IL-33. Overall, 
these observations suggest that IL-33 directly induces M2 macrophage polarisation and plays an important role 
in mucosal wound healing during colitis via the polarisation of M2 macrophages.
Discussion
Although IL-33 is synthesised as a precursor and can be cleaved by caspase-1 and -3, the cleavage products are 
biologically less active than their precursor40. To rule out the possibility that cleaved forms of IL-33 were unde-
tected in our assays and improve the recently proposed reliability issue of human IL-33 ELISA kit41, we used a 
complementary ELISA kit that analysed the presence of the C-terminal epitope of IL-33, in addition to an ELISA 
Figure 4. IL-33-treated peritoneal cavity cells ameliorate mouse colitis. Male C57BL/6 mice were inoculated 
i.p. with IL-33 (mrIL-33, 1 μg/mouse) or PBS for 3 consecutive days. Next, peritoneal cavity cells (PCCs) were 
extracted from the peritoneum of each mouse by washing the peritoneal cavity with cold PBS (a,b). F4/80 
positive cells were sorted from the harvested PCCs and i.p. injected (1 × 106 cells) into recipient mice. After 
2 days, 2,4,6-trinitrobenzenesulfonic acid (TNBS) solution (2.2% (w/v)) was injected into the colon of each 
recipient mouse (c–f). (a,b) Representative flow cytometry plots of PCCs and spleen cells from IL-33-treated 
naïve mice. (a) Dot plot of the M2 (CD206+) macrophage (F4/80+) populations in the PCCs and percentages of 
the M2 macrophage populations in the PCCs. (b) Treg (Foxp3+) and Th1 (Gata3+) populations in the spleens of 
naïve mice. (c) Body weight changes of PCC-transplanted mice. (d) Colon lengths of PCC-transplanted mice. 
(e) Disease activity index (DAI) scores of PCC-transplanted mice. (f) Flow cytometry analysis of Treg (Foxp3+) 
and Th1 (Gata3+) populations isolated from the spleen of PCC-transplanted mice. Values are expressed as 
means (n = 5); error bars represent ±SD. #P < 0.05 vs. TNBS, ##P < 0.01 vs. TNBS, *P < 0.05 vs. Veh or PBS 
PCC, **P < 0.01 vs. Veh or PBS PCC as assessed by ANOVA. Veh, injected with vehicle; IL-33, injected with 
mrIL-33; PCC, injected with F4/80+ PCCs; TNBS, injected with TNBS.
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kit used in a previous study2, 4. Both kits showed the same results, i.e. serum IL-33 levels were lower in patients 
with IBD compared with normal control patients. Consistent with the present study, some studies have reported 
that IL-33 is barely detected in serum samples from patients with UC and CD3, 4. However, several other studies 
have concluded that serum IL-33 levels are elevated in patients with IBD2–4. Despite these discrepancies, a general 
consensus is that IL-33 levels are upregulated in inflamed IBD tissues, especially in UC. As mentioned above, the 
increased IL-33 levels in the intestine during murine colitis might be due to an endogenous secondary compensa-
tory mechanism to restore the epithelium against tissue damage by increased proinflammatory cytokines such as 
TNF and IL-1β2, 42, 43. Alternatively, they may be due to decreased levels in ST2, a decoy receptor for IL-33, in IECs 
resulting from active inflammation itself. In this context, recently, genetic studies have shown that IL-33 mRNA 
levels are not correlated with allele dosage, although genetic polymorphisms in IL-33 contributing to the risk of 
IBD have been reported2, 4–6, 44. The increased sST2 serum levels that have been observed in patients with active 
UC suggest that sST2 might be involved in controlling the progress of UC, as has been proposed before4, although 
the precise role of sST2 in IBD remains unknown9. A particularly interesting finding of our study is that higher 
serum sST2 levels were associated with more severe disease in patients with UC, although this trend was not sig-
nificant in patients with CD or intestinal BD. Indeed, high levels of sST2 during chronic intestinal inflammation 
may further perpetuate pathogenic responses by limiting IL-33-driven Treg accumulation29. Moreover, it has also 
been reported that sST2 mRNA levels are significantly higher in patients with active UC4 and that ST2 deficiency 
results in decreased disease severity in two experimental models of IBD9. sST2 can serve as a decoy receptor 
for IL-3345, and conversely IL-33 upregulates sST2 expression, which in turn reduces IL-33 levels46, suggesting 
that sST2 might mask the protective function of IL-33. Additionally, ST2 can blunt macrophage activation by 
sequestering components in the toll-like receptor 4 (TLR4)/MyD88 pathway, a pathway that is required for IL-33 
signalling and gut homeostasis38, 47. Taken together, these findings are consistent with our finding that the serum 
IL-33 levels are reduced in patients with IBD. They also support the idea that reduced IL-33 production in colitis 
can help amplify and maintain pathogenic responses in the gut. However, we note that some studies have reached 
conclusions that are not completely in line with ours.
Figure 5. IL-33-treated peritoneal cavity cells rescue M2 macrophages and the goblet cells in colon tissues 
with colitis. (a) Representative flow cytometry plots of M2 (CD206+) macrophage (F4/80+) populations in 
colon samples. (b–d) Effects of IL-33 on the mRNA expression levels of M2 (Cd206 and Cd163, b), M1 marker 
(Tnfa, c), and goblet cell marker (Klf4, D) in the colons. (e) Representative periodic acid-Schiff (PAS) staining 
of colonic mucosal samples. Original magnification: x200. Values are expressed as means (n = 5); error bars 
represent ±SDs. *P < 0.05 vs. PBS PCC as assessed by ANOVA. PCC, peritoneal cavity cell; Veh, injected with 
vehicle; IL-33, injected with mrIL-33; TNBS, injected with TNBS.
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Recently, IL-33 has emerged as an important mediator of mucosal healing and repair in UC and CD2, 11. 
Because of its nuclear localisation sequence, IL-33 has been proposed to act as a chromatin-associated transcrip-
tional regulating factor23. Interestingly, nuclear localisation of IL-33 has been observed in IBD23, suggesting that 
IL-33 may directly modulate goblet cell or macrophage differentiation. Consistent with this hypothesis and previ-
ous studies2, 4, we confirmed that IL-33 is localised in the nucleus in both enterocytes and macrophages of human 
and mouse colons and that IL-33 induces goblet cell hyperplasia, although further studies are required to test the 
hypothesis that IL-33 directly regulates genes related to goblet cell differentiation. Since goblet cell depletion is a 
sign of gut inflammation and a histological criterion for IBD, failure to produce mature goblet cells may compro-
mise mucin production, resulting in a weakened mucosal barrier and chronic gut inflammation elicited by proin-
flammatory cytokines48. Crypt architectural abnormalities accompanied by goblet cell loss have been observed in 
patients with UC patients with decreased MUC2 production49 and IL-33 expression4. Consistently, IL-33 has been 
Figure 6. IL-33 drives goblet cell restoration and wound healing via modulation of macrophages toward the 
M2 phenotype. (a,b) Effects of IL-33-treated macrophage on goblet cell differentiation. THP-1 monocyte-
derived macrophages were treated with vehicle (Veh) or lipopolysaccharide (LPS, 100 ng/ml), with or without 
IL-33 (20 ng/ml) for 48 hours. Conditioned media from the macrophages were harvested. HT-29 and SW480 
cells were treated with normal control media (NC) or the conditioned media for 48 h. Total RNA was extracted 
from HT-29 and SW480 cells and analysed by quantitative RT-PCR MUC2 (a) and KLF4 (b) mRNA expression 
levels were normalised to that of β-actin. Data are presented as means ± SD (n = 4). (c) Co-localisation of 
IL-33 and CD206 in human colon tissues. Representative images showing that IL-33 is localised to colonic 
intestinal epithelial cells and lamina propria mononuclear cells. Moreover, IL-33 expression is markedly 
increased in CD206+ cells (M2 macrophages). The immunolocalisation of IL-33 (red) and CD206 (green) in 
colon tissue samples from normal controls (NC, n = 3) and patients with ulcerative colitis (UC, n = 4) was 
evaluated by immunohistochemistry using fluorescent conjugated antibodies. Nuclei were counterstained with 
DAPI (blue). Original magnification: x400. (d,e) IL-33 drives human monocyte-derived macrophages toward 
the M2 phenotype and wound repair. Monocytes were isolated from PBMCs (peripheral blood mononuclear 
cells) and differentiated into macrophages using human recombinant GM-CSF for 7 days. Macrophages were 
cocultured with the HT-29 cells and wound healing assays were performed. (d) Representative images of 
CD206+ cells. Monocyte-derived macrophages from patients with IBD (n = 2) were treated with IL-33 and 
stained with fluorescent antibodies against CD206 (red). Nuclei were counterstained with DAPI (blue). Original 
magnification: x400. (e) Wound healing assay. Monocytes were isolated from PBMCs and differentiated into 
macrophages for 7 days. HT-29 cells were cocultured with or without the macrophages (NC) and wound 
healing assays were performed. Data are presented as means ± SD (n = 3). *P < 0.05 vs. LPS, **P < 0.01 vs. LPS, 
***P < 0.005 vs. LPS as assessed by Student’s t-test. Veh, treated with vehicle; IL-33, treated with hrIL-33; LPS, 
treated with lipopolysaccharide; α-IL-33, treated with anti-IL-33 antibodies (IL-33 antagonist).
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 851  | DOI:10.1038/s41598-017-00840-2
reported to increase goblet cell hyperplasia36, 47; furthermore, IL-33 deficiency depletes goblet cells42. However, 
IL-33 in our study did not exacerbate the disease activity, but ameliorated the colitis. These controversial results 
suggest that the function of IL-33 in inflammation might be dependent on the balance between IL-33 and the 
degree and/or type of immune response. Although a previous study concluded that IL-33 induces goblet cell 
differentiation via a Th2 response and promotes epithelial repair from injury27, we did not observe any changes in 
the splenic population of Th2 cells after IL-33 treatment. A significant proportion of intestinal Foxp3+ Treg cells 
have been shown to coexpress the transcription factor Gata328, 29. Interestingly, IL-23 inhibits the expression of 
Gata3 and ST229, suggesting that the upregulation of IL-23 in colitis might limit T-cell responsiveness and Treg 
differentiation in response to IL-3329. Such a scenario would partly explain why T-cell responsiveness was reduced 
in our colitis models. Of note, MyD88-deficient mice showed no difference of goblet cell modulation by IL-33 
during colitis when compared with wild-type mice. Taken together, our results indicate that goblet cell modula-
tion by IL-33 might be directly influenced by IL-33 itself or by other non-T cells, such as macrophages, but inde-
pendently of the MyD88 pathway during colitis. In this context, we found for the first time that the conditioned 
media from IL-33-treated macrophages enhances more dramatically goblet cell differentiation when compared to 
IL-33-alone treatment and IL-33-treated F4/80+ cell administration modulates goblet cell differentiation in vivo. 
These findings suggest that M2 polarization of macrophages may function as another critical modulator of goblet 
cells. KLF-4 is a C2H2 zinc-finger containing transcription factor that is highly expressed in the gastrointestinal 
tract50 and required for the terminal differentiation of goblet cells in the colon35. Previous studies indicate that 
suppression of notch signalling increases Klf4 levels51 and IL-33 suppresses notch ligand expression and prevents 
goblet cell depletion in DSS-induced colitis12. Consistently, we demonstrated that IL-33 increases directly and via 
macrophage KLF4 expression in vitro and in vivo, which might lead to restoration of goblet cells by suppression 
of Notch signalling. Further study to discover a pathway associated with goblet cell modulation by IL-33 during 
colitis is warranted.
We observed a trend of significantly increased IL-33 expression in colonic mucosal samples and an association 
of serum sST2 with disease activity in UC but not in CD. These findings might be correlated with the relative 
predominance of Th2 polarisation and ST2 transcription in UC, in contrast to CD, which is Th1-skewed4. In 
UC, the affected organs accumulate a heterogeneous population of macrophages derived from recruited mono-
cytes. Furthermore, IL-33 can promote macrophage polarisation towards the M2 phenotype in mouse bone 
marrow-derived macrophages, which enhances type-2 cell-mediated immune responses in airway inflamma-
tion22. IL-33 has been proposed to promote M2 macrophage development and to enhance TGF-β expression52. 
TGF-β is important because it can also be produced from M2 macrophages and has been proposed to be a major 
factor responsible for the induction of Tregs29. We found that IL-33 induced M2 macrophages in both mouse 
models of colitis and human MDMs, even though IL-33 did not significantly affect Th2 or Treg populations in the 
mouse models. Since M2 macrophages derived from M1 macrophages improve the resolution of inflammation 
and aid wound healing18, our results suggest that IL-33 ameliorates colitis via the modulation of macrophages, not 
of T-cells and, notably, Treg and Th2 cells are dispensable for IL-33-mediated amelioration of colitis in our system, 
similar to that of a recent studies14, 53. Our data suggest that IL-33 ameliorates colitis through its effects on innate 
immunity rather than adaptive immunity. However, further studies using ST2-deficient mice would be valuable 
to determine the precise mechanism by which IL-33 induces M2 macrophages.
We focused our present effort on macrophages. In this study, we demonstrated that patients with IBD have 
lower serum IL-33 levels than healthy controls. Our data suggest that IL-33 facilitates wound healing and ame-
liorates colitis via modulating the differentiation of goblet cells and M2 macrophages independent of the MyD88 
pathway and T-cells. This is the first study to dissect the mechanisms by which IL-33 both directly and indirectly 
modulates the functions of enterocytes and macrophages in the context of mucosal healing and wound repair 
during colitis. Our findings, therefore, imply that IL-33 contributes to the resolution of colitis via modulation of 
macrophages and plays a crucial protective role in IBD.
Methods
Study subjects. Forty five healthy subjects, 69 patients with CD, 75 patients with UC, and 74 patients with 
intestinal BD of Korean descent were recruited at Severance Hospital (Yonsei University College of Medicine, 
Seoul, Korea) between June 2006 and August 2014. At all times, diagnosis of BD54, CD55, and UC55 was made 
according to previously established international criteria based on clinical, endoscopic, histopathological, and 
radiological findings. Patients who were diagnosed or suspected as having indeterminate colitis, coexistence of 
infectious or ischemic colitis, coexistence of other localised or systemic infections, any malignant diseases, or any 
major systemic illnesses were excluded. Disease localisation and CD behaviour were described according to the 
Montreal classification scheme56. The CDAI, pMayo, and DAIBD scores were also recorded for each patient at the 
time of the hospital visit. The control group comprised healthy individuals who had no history of immune-medi-
ated diseases. The demographic and clinical characteristics of the study subjects are summarised in Table S1. This 
study was approved by the Institutional Review Board of Severance Hospital, Yonsei University (IRB approval 
number 4-2012-0302). All patients and controls provided written informed consent and all the experiments that 
involved human subjects were carried out in accordance with the approved guidelines by the IRB.
Colonic mucosal tissue preparation, monocyte isolation from peripheral blood mononuclear 
cells (PBMCs), and cell culture. Serum samples were obtained from heparin-treated blood by centrif-
ugation at 1,500 g for 15 minutes and stored at −80 °C until processed. Colonic mucosal tissue samples were 
collected during colonoscopy, immediately snap-frozen in liquid nitrogen, and stored at −80 °C until use. 
PBMCs were isolated from healthy donors using density gradient centrifugation with Ficoll-Paque Plus (GE 
Healthcare, Piscataway, NJ, USA). Briefly, cells were spun at 1,000 g for 15 minutes. Monocytes were obtained 
from the remaining cells by magnetic sorting using a human Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch 
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Gladbach, Germany). The obtained monocytes were activated using human recombinant GM-CSF (hrGM-CSF, 
100 ng/ml, Promokine, Heidelberg, Germany) and cultured in RPMI1640 containing 10% heat-inactivated foe-
tal bovine serum (FBS, HyClone, Logan, UT, USA) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, 
USA) for 4 days. Activated monocytes were then divided into the following 7 treatment groups: Veh (vehicle), 
LPS (1 μg/ml, Sigma-Aldrich, St. Louis, MO, USA), LPS + hrIL-33 (human recombinant IL-33: Ser109-Ile266, 
20 ng/ml, Biolegend, San Diego, CA, USA), hrIL-33, α-IL-33 (rabbit anti-human IL-33 antibodies, 1 μg/ml, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), and LPS + α-IL-33. After 24 hours, macrophages were detached 
with a cell scraper (SPL Life Science Inc., Daejeon, South Korea) and analysed by flow cytometry. Alternatively, 
macrophages were cocultured with HT-29 cells for the in vitro wound healing assay or cultured in a confocal dish 
(SPL Life Science Inc.) for immunofluorescence (IF) staining. HT-29 and SW480, intestinal epithelial cancer cell 
line (American Type Culture Collection: ATCC), were grown to 80% confluency in RPMI 1640 medium supple-
mented with 10% FBS and 1% penicillin/streptomycin under standard conditions (humidified atmosphere of 5% 
CO2 at 37 °C). Macrophages were obtained after differentiation of THP-1 cells provided by the American Type 
Culture Collection (TIB-202TM, ATCC, Rockville, MD, USA). THP-1 cells (ATCC) known to differentiate into 
macrophages after stimulation with phorbol myristate acetate (PMA, Sigma-Aldrich)57 were cultured in RPMI. 
To obtain macrophages, THP-1 cells were stimulated with PMA (30 nM) for 24 h and washed with PBS 3 times 
before treatment. Cells were cultured with or without LPS (200 ng/ml; Sigma-Aldrich) for 0, 2, 6, 12, 24, and 48 h. 
Supernatants were immediately collected, aliquoted, and frozen at −20 °C for later assays; cells were harvested for 
total protein extraction.
Determination of serum concentrations of IL-33 and soluble receptor ST2 (sST2). Serum IL-33 
and sST2 concentrations were determined in duplicate using ELISA kits to detect the C-terminal epitope of IL-33 
(LEGEND MAX™ Human IL-33 ELISA Kit, BioLegend; DuoSet IL-33 ELISA kit, R&D Systems, Minneapolis, 
MN, USA) and sST2 (R&D Systems), respectively, in accordance with the manufacturer’s recommended pro-
tocols. Briefly, serum samples were incubated in 96-well plates that had previously been coated with anti-IL-33 
and sST2-specific monoclonal antibodies for 2 hours at room temperature. After washing the wells four times, 
peroxidase-conjugated polyclonal antibodies against IL-33 and sST2 were added. Samples were incubated for 
2 hours at room temperature followed by four washes, after which the substrate solution was added. After incu-
bation for 30 minutes at room temperature, the reactions were terminated by the addition of stop solution. The 
optical density of each well at 450 nm was determined using a VersaMax ELISA Microplate Reader (Molecular 
Devices, Sunnyvale, CA, USA). All values were corrected by normalising to the corresponding absorbances at 
540 nm. All data were analysed with SoftMax Pro 6.3 (Molecular Devices).
DSS, TNBS, and PCC transfer animal studies. To induce acute colitis, 8–9-week-old male C57BL/6 
mice were administered 3% (w/v) DSS (MP Biomedicals, Solon, OH, USA) in their drinking water. The first 
day of administration was designated day 0; DSS was administered for 6 consecutive days. The mice received 
i.p. mouse recombinant IL-33 (mrIL-33, 0.2 μg/mouse, BioLegend) or PBS daily from days 1 to 5. On day 7, the 
day before sacrifice, the drinking water with DSS was replaced with plain drinking water. For TNBS-induced 
colitis, mice were lightly anaesthetised with 2 mg/kg Zoletil (Virbac Laboratories, Carros, France) and 10 mg/kg 
xylazine (Rompun, Hver-Lockhart Laboratories, Shawnee Mission, KS, USA) by i.p. injection. A total of 100 µl 
TNBS solution (1.8% (w/v) for mild colitis, 2.2% (w/v) in the PCC and survival models; Sigma-Aldrich) in 40% 
ethanol (Sigma-Aldrich) was injected into the colon of the mouse via the anus using a 1 ml syringe equipped with 
a round thin-tip needle. After insertion into the colon approximately 4 cm from the anus, the mice were hung in 
a head-down position for 2 min to allow the administered agents to be distributed entirely throughout the colon 
and caecum. The normal group was treated with vehicle only. The mice were evaluated daily for body weight loss, 
the presence of gross blood in the faeces or at the anus, stool consistency and overall mortality. A validated DAI 
score previously used in our study58 was calculated for each mouse before sacrifice. The score ranged from 0 to 
4 and was calculated based on the following parameters: weight loss (0, none; 1, 1–5%; 2, 5–10%; 3, 10–20%; 4, 
>20%), gross bleeding (0, absence; 2 and 3, light bleeding; 4, bleeding), and stool consistency (0, negative; 1 and 
2, loose; 3 and 4, diarrheal). DAI scores were expressed as the average of these three parameters. The severity of 
colitis was assessed by an independent observer who was blinded to mouse assignments. Mouse recombinant 
IL-33 (mrIL-33, 1 μg/mouse) or sterilised PBS (vehicle) was injected into naive mice for the PCC transfer model 
and for the other TNBS model. In the PCC transfer model, PCCs were extracted from the peritoneum of each 
mouse by washing the peritoneal cavity with cold PBS at 3 days post-IL-33 i.p. injection. From these harvested 
cells, F4/80 positive cells were sorted using a FACSAria flow cytometer (BD Bioscience, San Jose, CA, USA). Next, 
1 × 106 sorted cells were i.p. injected into the recipient mice. After 2 days, the recipient mice were lightly anaesthe-
tised and injected with TNBS solution. At 4 days post-TNBS treatment, which corresponded to 7 days post-DSS 
administration, the mice were euthanised and the entire colon (from the cecum to the anus) was quickly removed 
from each mouse. The colon length from the ileo–caecal junction to the proximal rectum was measured, after 
which a longitudinal incision was made along the entire colon and all stool was eliminated by washing with 
PBS. Subsequently, the distal colon was divided into 3 portions for PAS staining, immunofluorescence, and RNA 
isolation. All recipient mice were fed a standard diet until reaching the age at which the experiment began. All 
animal experiments were performed according to all applicable Korean laws and were reviewed and approved by 
the Institutional Animal Care and Use Committee of Yonsei University Severance Hospital, Seoul, Korea (IACUC 
Approval No: 2013-0166) and were carried out in accordance with the approved guidelines by the IACUC.
Isolation of macrophages from the colon and isolation of lymphocytes from the spleen. Lamina 
propria mononuclear cells (LPMCs) were isolated from the harvested mouse colons as previously described59. 
Briefly, each spleen was cut into small fragments. The fragments were passed through a 70-mm pore cell strainer 
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(BD Bioscience) into a 60 mm culture dish. The dish contained 4 ml RPMI 1640 medium supplemented with 
10% heat-inactivated foetal bovine serum and 1% antibiotics. Next, the tissue fragments were crushed using the 
plunger of a 2 ml syringe and the crushed tissues were harvested. After depletion of red blood cells with RBC lysis 
buffer, the remaining cells were analysed by flow cytometry.
PAS staining, histology, and immunofluorescence. Animal and human tissue samples were fixed with 
10% formalin solution (pH 7.4) overnight, embedded on a slide with paraffin and sectioned using standard pro-
tocols. Sections were then deparaffinised, incubated in warm 1% citrate buffer for 10 min, cooled at room tem-
perature for 1 hour and then washed with distilled water for 2 min before antigen retrieval. Nonspecific binding 
sites were blocked by incubation in 1% BSA/PBS for surface molecule staining; to detect intracellular compo-
nents, blocking was performed with 1% BSA/PBS with 0.1% Triton X-100. Subsequently, rabbit anti-human IL-33 
(1:200, Santa Cruz) and FITC-conjugated CD206 (1:50, BD Bioscience) antibodies were added to the sections 
and incubated at 4 °C overnight. IL-33 signal was detected with goat anti-rabbit IgG Alexa Fluor 555 antibodies 
(1:500, Invitrogen). Nuclei were counterstained with DAPI (blue). Images were obtained using a fluorescence 
light microscope (Olympus BX41, Olympus Optical, Tokyo, Japan).
Flow cytometry. Cell suspensions were prepared in PBS containing 2% FBS. Cells (1 × 106) were blocked 
with mouse Fc blocking solution (anti-mouse CD16/CD32 mAb 2.4G2, BD Bioscience) and stained for 30 min-
utes at 4 °C with the appropriate antibodies. The antibodies used included: human and mouse anti-Foxp3 (1:50, 
150D/E4) and anti-Gata3 (1:50, TWAJ) (eBioscience; San Diego, CA, USA); mouse anti-CD3 (1:50, 145-2C11), 
anti-CD4 (1:50, GK1.5) (BD Bioscience; F4/80), anti-BM8 (eBioscience), and anti-CD206 (1:50, C068C2) 
(BioLegend); and human anti-CD3 (1:50, SK7), anti-CD206 (1:50, 19.2) (BD Bioscience), anti-CD4 (1:50, 
OKT4), and anti-CD11b (1:50, ICRF4) (eBioscience). For intracellular staining, a Foxp3/Transcription factor 
staining buffer set was purchased from eBioscience. Data were acquired using a FACSVerse flow cytometer (BD 
Bioscience) and analysed using FlowJo software (Tree Star, San Carlos, CA, USA).
Extraction of RNA and quantitative real-time RT-PCR. Total RNA was extracted using TRIzol 
Reagent (Invitrogen) and reverse transcribed using a SuperScript First-Strand Synthesis Kit (Invitrogen) accord-
ing to the manufacturer’s protocol. Next, 20 ng of RNA was reverse-transcribed using a SuperScript First-Strand 
Synthesis kit (Life Technologies) according to the manufacturer’s protocol. Reactions contained cDNA, SYBR 
Green Master Mix (Applied Biosystems, Foster City, CA, USA) and the appropriate primer pair; all reactions 
were set up in triplicate. Amplification was performed using a StepOne Plus real-time PCR system (Applied 
Biosystems) for 45 cycles using the following thermocycling steps: 95 °C for 30 seconds, 60–63 °C for 30 seconds, 
and 72 °C for 40 seconds. Quantitative PCR (qPCR) primers are summarised in Table S2. Finally, quantitative 
analysis was performed using the relative comparative method using the following equation: relative gene expres-
sion = 2−(ΔCt sample−ΔCt control), and the results were reported as the fold change as compared to the calibrator or 2ΔCt 
after normalization of the transcript level to the endogenous control.
In vitro wound healing assay. HT-29 colon epithelial cells were cultured in 12-well plates under standard 
culture conditions until reaching 80% confluence. Next, wounds were created using a plastic tip and images were 
captured using a fluorescence microscope. The plates were marked to facilitate the identification of the same 
region at later time points. Next, monocytes cultured together with lymphocytes were added to the wounded 
HT-29 cells (5 × 105 cells/well). To estimate the degree of wound healing, images were captured every 12 hours 
and the percentage closure was calculated using cellSens software (Olympus Optical).
Statistical analysis. Associations between clinical and laboratory parameters and serum IL-33/ST2 levels 
were analysed by calculating Pearson’s correlation coefficients. All results are expressed as means of 3–5 sam-
ples ± standard deviation (SD) or ± standard error of mean (SEM). Prism software (GraphPad Software, Inc., 
San Diego, CA) was used for all analysis. The significance of differences between conditions was assessed using 
Student’s t-test and one–way ANOVA. P values < 0.05 were considered significant. *P < 0.05, **P < 0.005, and 
***P < 0.001 compared to the control condition.
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